IMMUNOVANT, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IMMUNOVANT, INC. (IMVT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $13.53M, a 26.43% decline year-over-year.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $12.53M, a 7.59% increase year-over-year.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $13.19M, a 3.95% increase year-over-year.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $18.39M, a 36.84% increase year-over-year.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $54.89M, a 10.98% increase from fiscal 2025.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $49.46M, a 20.60% increase from fiscal 2024.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $41.01M, a 28.30% increase from fiscal 2023.
- IMMUNOVANT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $31.97M, a 3.55% decline from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.53M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $54.89M 10-K · filed 2026-05-20 | |||
| 2025-12-31 | $12.53M 10-Q · filed 2026-02-06 | $25.72M derived: sum of 2 quarters · filed 2026-02-06 | $44.11M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-09-30 | $13.19M 10-Q · filed 2026-02-06 | $31.58M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $18.39M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $49.46M 10-K · filed 2026-05-20 | |||
| 2024-12-31 | $11.65M 10-Q · filed 2026-02-06 | $24.33M derived: sum of 2 quarters · filed 2026-02-06 | $37.78M derived: sum of 3 quarters · filed 2026-02-06 | |
| 2024-09-30 | $12.69M 10-Q · filed 2026-02-06 | $26.13M derived: sum of 2 quarters · filed 2026-02-06 | ||
| 2024-06-30 | $13.44M 10-Q · filed 2026-02-06 | |||
| 2024-03-31 | $41.01M 10-K · filed 2026-05-20 | |||
| 2023-12-31 | $10.20M 10-Q · filed 2025-02-06 | $20.70M derived: sum of 2 quarters · filed 2025-02-06 | $31.35M derived: sum of 3 quarters · filed 2025-02-06 | |
| 2023-09-30 | $10.50M 10-Q · filed 2025-02-06 | $21.15M derived: sum of 2 quarters · filed 2025-02-06 | ||
| 2023-06-30 | $10.65M 10-Q · filed 2025-02-06 | |||
| 2023-03-31 | $31.97M 10-K · filed 2025-05-29 | |||
| 2022-12-31 | $8.86M 10-Q · filed 2024-02-12 | $16.91M derived: sum of 2 quarters · filed 2024-02-12 | $24.46M derived: sum of 3 quarters · filed 2024-02-12 | |
| 2022-09-30 | $8.05M 10-Q · filed 2024-02-12 | $15.61M derived: sum of 2 quarters · filed 2024-02-12 | ||
| 2022-06-30 | $7.55M 10-Q · filed 2024-02-12 | |||
| 2022-03-31 | $33.14M 10-K · filed 2023-05-22 | |||
| 2021-12-31 | $9.95M 10-Q · filed 2023-02-03 | $17.62M derived: sum of 2 quarters · filed 2023-02-03 | $21.44M derived: sum of 3 quarters · filed 2023-02-03 | |
| 2021-09-30 | $7.67M 10-Q · filed 2023-02-03 | $11.49M derived: sum of 2 quarters · filed 2023-02-03 | ||
| 2021-06-30 | $3.82M 10-Q · filed 2023-02-03 | |||
| 2021-03-31 | $18.64M 10-K · filed 2022-06-08 | |||
| 2020-12-31 | $5.99M 10-Q · filed 2022-02-04 | $9.30M derived: sum of 2 quarters · filed 2022-02-04 | $13.22M derived: sum of 3 quarters · filed 2022-02-04 | |
| 2020-09-30 | $3.31M 10-Q · filed 2022-02-04 | $7.22M derived: sum of 2 quarters · filed 2022-02-04 | ||
| 2020-06-30 | $3.92M 10-Q · filed 2022-02-04 | |||
| 2020-03-31 | $6.79M 10-K · filed 2021-06-01 | |||
| 2019-12-31 | $1.33M 10-Q · filed 2021-02-16 | $4.45M derived: sum of 2 quarters · filed 2021-02-16 | $4.99M derived: sum of 3 quarters · filed 2021-02-16 | |
| 2019-09-30 | $3.12M 10-Q · filed 2021-02-16 | $3.66M derived: sum of 2 quarters · filed 2021-02-16 | ||
| 2019-06-30 | $537.00K 10-Q · filed 2021-02-16 | |||
| 2019-03-31 | $31.00K 10-K · filed 2020-06-29 | |||
| 2018-12-31 | $12.00K 10-Q · filed 2020-02-14 | $13.00K derived: sum of 2 quarters · filed 2020-02-14 | ||
| 2018-09-30 | $1.00K 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |